Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The current PI3K 3C inhibitors in use in ...
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. There are several clinical trials that are ...
Simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) is considered a good strategy in cancer treatment, although current PI3K/HDAC dual inhibitors have ...
Roche’s pitch to reset the standard of care in a breast cancer population has cleared a late-phase hurdle. The drugmaker’s attempt to improve on Novartis’ Piqray and deliver a first-line PI3K ...
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...
Forschungsverbund Berlin eV has divulged phosphatidylinositol 4-phosphate 3-kinase (PI3K) inhibitors, particularly PI3K C2 domain-containing subunit β (PIK3C2B) inhibitors, reported to be useful for ...
Immunohistochemical identification of SDHA-mutant gastrointestinal stromal tumors (GISTs). Neoadjuvant treatment of locally advanced GIST: Results of APOLLON, a prospective, open label phase II study ...
A study has uncovered a surprising link between diet, intestinal microbes and the efficacy of cancer therapy. A Ludwig Cancer Research study has uncovered a surprising link between diet, intestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback